Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL)

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(HOLME P) > (2005-2009) > Lipoprotein predict...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		04257naa a2200445 4500
001		oai:DiVA.org:liu-50220
003		SwePub
008		091011s2008 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-502202 URI
024	7	a https://doi.org/10.1080/078538908019649552 DOI
040		a (SwePub)liu
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Holme, I.u Center of Preventive Medicine, Ullevål University Hospital, Oslo, Norway, Department of Biostatistics, Centre for Preventive Medicine, Ullevål University Hospital, Kirkeveien 166, N-0407 Oslo, Norway4 aut
245	1 0	a Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL)
264		c 2009-07-08
264	1	b Informa UK Limited,c 2008
338		a print2 rdacarrier
520		a Background. Few studies have looked into the ability of measurements of apolipoprotein B (apoB) and apolipoprotein A-1 (apoA-1) or apoB/apoA-1 to predict new coronary heart disease (CHD) events in patients with CHD on statin treatment. Aims. In the IDEAL trial, to compare lipoprotein components to predict CHD events and to what degree differences in those parameters could explain the observed outcome. Methods. We compared the ability of treatment with atorvastatin 80 mg/day to that of simvastatin 20-40 mg/day to prevent CHD events in patients with CHD and used Cox regression models to study the relationships between on-treatment levels of lipoprotein components to subsequent major coronary events (MCE). Findings. Variables related to low-density lipoprotein cholesterol (LDL-C) carried more predictive information than those related to high-density lipoprotein cholesterol (HDL-C), but LDL-C was less predictive than both non-HDL-C and apoB. The ratio of apoB to apoA-1 was most strongly related to MCE. However, for estimating differences in relative risk reduction between the treatment groups, apoB and non-HDL-C were the strongest predictors. Interpretation. The on-treatment level of apoB/apoA-1 was the strongest predictor of MCE in the pooled patient population, whereas apoB and non-HDL-C were best able to explain the difference in outcome between treatment groups. Measurements of apoB and apoA-1 should be more widely available for routine clinical assessments. © 2008 Informa UK Ltd. (Informa Healthcare, Taylor & Francis AS).
653		a Apolipoproteins
653		a CHD
653		a Lipoproteins
653		a Prediction
653		a Statin treatment
653		a NATURAL SCIENCES
653		a NATURVETENSKAP
700	1	a Cater, N.B.u Pfizer, Pfizer Inc., New York, NY, United States4 aut
700	1	a Faergeman, O.u Department of Medicine-Cardiology A, Århus University Hospital, Århus, Denmark4 aut
700	1	a Kastelein, J.J.P.u Department of Vascular Medicine, Academic Hospital Amsterdam, Amsterdam, Netherlands4 aut
700	1	a Olsson, Anders G.u Östergötlands Läns Landsting,Linköpings universitet,Internmedicin,Hälsouniversitetet,Endokrin- och magtarmmedicinska kliniken US4 aut0 (Swepub:liu)andol21
700	1	a Tikkanen, M.J.u Department of Medicine, Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland4 aut
700	1	a Lytken, Larsen M.u Lytken Larsen, M., Department of Medicine-Cardiology A, Århus University Hospital, Århus, Denmark4 aut
700	1	a Lindahl, C.u Pfizer Sweden, Sollentuna, Sweden4 aut
700	1	a Pedersen, T.R.u Center of Preventive Medicine, Ullevål University Hospital, Oslo, Norway4 aut
710	2	a Center of Preventive Medicine, Ullevål University Hospital, Oslo, Norway, Department of Biostatistics, Centre for Preventive Medicine, Ullevål University Hospital, Kirkeveien 166, N-0407 Oslo, Norwayb Pfizer, Pfizer Inc., New York, NY, United States4 org
773	0	t Annals of Medicined : Informa UK Limitedg 40:6, s. 456-464q 40:6<456-464x 0785-3890x 1365-2060
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-50220
856	4 8	u https://doi.org/10.1080/07853890801964955

Hitta via bibliotek

Annals of Medicine (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Holme, I.; Cater, N.B.; Faergeman, O.; Kastelein, J.J.P ...; Olsson, Anders G ...; Tikkanen, M.J.; visa fler...; Lytken, Larsen M ...; Lindahl, C.; Pedersen, T.R.; visa färre...

Artiklar i publikationen: Annals of Medici ...

Av lärosätet: Linköpings universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se